financetom
Business
financetom
/
Business
/
TD SYNNEX Up Over 5% After Q1 Earnings: What's Going On?
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
TD SYNNEX Up Over 5% After Q1 Earnings: What's Going On?
Mar 26, 2024 9:52 AM

TD SYNNEX Corporation ( SNX )  shares are rising on Tuesday.

The company reported first quarter adjusted earnings per share of $2.99, beating the street view of $2.84.

The company reported quarterly revenue of $13.975 billion, missing the analyst view of $14.357 billion.

On a constant currency basis, revenue decreased by 8.3% compared to the prior fiscal first quarter. 

Non-GAAP gross billings were $19.3 billion in the quarter under review, compared to $20.2 billion in the prior fiscal first quarter.

First-quarter non-GAAP gross profit was $1.006 billion, compared to $1.011 billion in the prior fiscal first quarter. Non-GAAP gross margin was 7.2%, compared to 6.7% in the prior fiscal first quarter. 

The company said it returned $235 million to shareholders in the form of share repurchases and dividends, up 59% from the prior fiscal first quarter. 

TD SYNNEX Board of Directors has approved a share repurchase program of up to $2 billion of its common stock, supplementing the existing program of approximately $197 million remaining. 

The company declared a quarterly cash dividend of $0.40 per common share. The dividend is payable on April 26, 2024, to stockholders of record as of the close of business on April 12, 2024.

Outlook: TD SYNNEX ( SNX ) expects second-quarter revenues of $13.3 billion- $14.9 billion versus the $14.25 billion estimate.

The company sees adjusted earnings per share of $2.50-$3.00 versus the $2.78 estimate.

According to Benzinga Pro, SNX stock has gained 20% in the past year. Investors can gain exposure to the stock via Invesco Exchange-Traded Fund Trust II Invesco S&P MidCap 400 Revenue ETF 

 and Invesco S&P Midcap 400 Pure Value ETF ( RFV ) .

Price Action: SNX shares are trading higher by 5.04% to $110.75 on the last check Tuesday.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Duolingo Insider Sold Shares Worth $1,712,448, According to a Recent SEC Filing
Duolingo Insider Sold Shares Worth $1,712,448, According to a Recent SEC Filing
Mar 26, 2025
04:20 PM EDT, 03/26/2025 (MT Newswires) -- Robert Meese, Chief Business Officer, on March 24, 2025, sold 5,351 shares in Duolingo ( DUOL ) for $1,712,448. Following the Form 4 filing with the SEC, Meese has control over a total of 137,405 Class A common shares of the company, with 133,805 shares held directly and 3,600 controlled indirectly. SEC Filing:...
Ukraine may sign economic deal next week, US Treasury chief tells Fox News
Ukraine may sign economic deal next week, US Treasury chief tells Fox News
Mar 26, 2025
WASHINGTON (Reuters) - U.S. Treasury Secretary Scott Bessent said on Wednesday Ukraine may sign an economic deal next week and President Donald Trump will not hesitate to raise sanctions on Russia if the need arises. Bessent made the comments in an interview on the Fox News show The Story with Martha MacCallum, after he was asked for an update on...
Cassava Sciences must face malicious prosecution lawsuit over Alzheimer's drug
Cassava Sciences must face malicious prosecution lawsuit over Alzheimer's drug
Mar 26, 2025
NEW YORK (Reuters) -The biotechnology company Cassava Sciences ( SAVA ) failed on Wednesday to end a malicious prosecution lawsuit by doctors and short-sellers who expressed doubts about its experimental, soon-to-be-discontinued Alzheimer's drug simufilam. U.S. District Judge Jennifer Rochon in Manhattan said Adrian Heilbut, Jesse Brodkin, Enea Milioris, David Bredt and Geoffrey Pitt could try to prove that Cassava knew...
Immunome Insider Bought Shares Worth $999,459, According to a Recent SEC Filing
Immunome Insider Bought Shares Worth $999,459, According to a Recent SEC Filing
Mar 26, 2025
04:11 PM EDT, 03/26/2025 (MT Newswires) -- Clay B Siegall, Director, President and CEO, on March 26, 2025, executed a purchase for 137,100 shares in Immunome ( IMNM ) for $999,459. Following the Form 4 filing with the SEC, Siegall has control over a total of 806,736 common shares of the company, with 806,736 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1472012/000141588925009017/xslF345X05/form4-03262025_080357.xml...
Copyright 2023-2026 - www.financetom.com All Rights Reserved